211 related articles for article (PubMed ID: 34681263)
1. Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review.
La Salvia A; Sesti F; Grinzato C; Mazzilli R; Tarsitano MG; Giannetta E; Faggiano A
Pharmaceuticals (Basel); 2021 Oct; 14(10):. PubMed ID: 34681263
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).
Lopez CL; Joos B; Bartsch DK; Manoharan J; Albers M; Slater EP; Bollmann C; Roth S; Bayer A; Fendrich V
World J Surg; 2019 Mar; 43(3):831-838. PubMed ID: 30600364
[TBL] [Abstract][Full Text] [Related]
3. Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs).
Grozinsky-Glasberg S; Lines KE; Avniel-Polak S; Bountra C; Thakker RV
Endocr Relat Cancer; 2020 Sep; 27(9):R345-R355. PubMed ID: 32590358
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of clinical features between sporadic pancreatic neuroendocrine tumors and those associated with multiple endocrine neoplasia type 1].
Gu DY; Fu Q; Xue BY; Kan JB; Bai JA; Tang QY
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):1014-1019. PubMed ID: 35399021
[No Abstract] [Full Text] [Related]
5. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.
Ramundo V; Del Prete M; Marotta V; Marciello F; Camera L; Napolitano V; De Luca L; Circelli L; Colantuoni V; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A;
Clin Endocrinol (Oxf); 2014 Jun; 80(6):850-5. PubMed ID: 24443791
[TBL] [Abstract][Full Text] [Related]
6. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain.
Bartsch DK; Slater EP; Albers M; Knoop R; Chaloupka B; Lopez CL; Fendrich V; Kann PH; Waldmann J
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2387-91. PubMed ID: 25210877
[TBL] [Abstract][Full Text] [Related]
7. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
[TBL] [Abstract][Full Text] [Related]
8. Preoperative Imaging Overestimates the Tumor Size in Pancreatic Neuroendocrine Neoplasms Associated with Multiple Endocrine Neoplasia Type 1.
Polenta V; Slater EP; Kann PH; Albers MB; Manoharan J; Ramaswamy A; Mahnken AH; Bartsch DK
World J Surg; 2018 May; 42(5):1440-1447. PubMed ID: 29075857
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention with Enalapril and Aspirin in Men1(+/T) Knockout Mouse Model.
Manoharan J; Fendrich V; Di Fazio P; Bollmann C; Roth S; Joos B; Mintziras I; Albers MB; Ramaswamy A; Bertolino P; Zhang CX; Slater EP; Bartsch DK; Lopez-Lopez CL
Neuroendocrinology; 2018; 107(3):257-266. PubMed ID: 30025403
[TBL] [Abstract][Full Text] [Related]
10. The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome.
Cioppi F; Cianferotti L; Masi L; Giusti F; Brandi ML
Clin Cases Miner Bone Metab; 2017; 14(2):123-130. PubMed ID: 29263719
[TBL] [Abstract][Full Text] [Related]
11. Whole-exome sequencing as a tool for searching for genetic background modifiers in MEN1 patients with neuroendocrine pancreatic tumours, including insulinomas.
Skalniak A; Trofimiuk-Müldner M; Jabrocka-Hybel A; Totoń-Żurańska J; Wołkow P; Hubalewska-Dydejczyk A
Endokrynol Pol; 2023; 74(1):31-46. PubMed ID: 36847722
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of clinical characteristics between sporadic gastrinoma and multiple endocrine neoplasia type 1-related gastrinoma].
Guo Y; Chen LH; Liu M; Zhang YX; Zhang N; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Oct; 24(10):875-882. PubMed ID: 34674462
[No Abstract] [Full Text] [Related]
13. Patient characteristics and clinical outcomes following initial surgical intervention for MEN1 associated pancreatic neuroendocrine tumours: A systematic review and exploratory meta-analysis of the literature.
Ratnayake CBB; Loveday BP; Windsor JA; Lawrence B; Pandanaboyana S
Pancreatology; 2019 Apr; 19(3):462-471. PubMed ID: 30894303
[TBL] [Abstract][Full Text] [Related]
14. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries.
Tonelli F; Marini F; Giusti F; Iantomasi T; Giudici F; Brandi ML
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894286
[TBL] [Abstract][Full Text] [Related]
16. A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival.
Massironi S; Rossi RE; Zilli A; Casazza G; Ciafardini C; Conte D
Oncotarget; 2016 Apr; 7(14):18978-83. PubMed ID: 26959887
[TBL] [Abstract][Full Text] [Related]
17. Enucleation and limited pancreatic resection provide long-term cure for insulinoma in multiple endocrine neoplasia type 1.
Bartsch DK; Albers M; Knoop R; Kann PH; Fendrich V; Waldmann J
Neuroendocrinology; 2013; 98(4):290-8. PubMed ID: 24356648
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic Neuroendocrine Neoplasias in Multiple Endocrine Neoplasia Type 1 Are Predominantly Located in the Dorsal Anlage: An Endoscopic Ultrasound Study.
Kann PH; Scheunemann A; Dorzweiler P; Adelmeyer J; Bergmann S; Goebel JN; Mann V; Bartsch DK; Holzer K; Albers MB; Manoharan J; Scheunemann LM
Pancreas; 2021 Sep; 50(8):1169-1172. PubMed ID: 34714280
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study.
Lamarca A; McCallum L; Nuttall C; Barriuso J; Backen A; Frizziero M; Leon R; Mansoor W; McNamara MG; Hubner RA; Valle JW
Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):723-731. PubMed ID: 29923433
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
